25 XP   0   0   10

Adaptive Biotechnologies Corp
Buy, Hold or Sell?

Let's analyse Adaptive Biotechnologies Corp together

PenkeI guess you are interested in Adaptive Biotechnologies Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Adaptive Biotechnologies Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Adaptive Biotechnologies Corp

I send you an email if I find something interesting about Adaptive Biotechnologies Corp.

Quick analysis of Adaptive Biotechnologies Corp (30 sec.)










What can you expect buying and holding a share of Adaptive Biotechnologies Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.09
Expected worth in 1 year
$1.03
How sure are you?
12.5%

+ What do you gain per year?

Total Gains per Share
$-1.06
Return On Investment
-27.8%

For what price can you sell your share?

Current Price per Share
$3.80
Expected price per share
$2.28 - $4.49
How sure are you?
50%

1. Valuation of Adaptive Biotechnologies Corp (5 min.)




Live pricePrice per Share (EOD)

$3.80

Intrinsic Value Per Share

$-3.95 - $-4.14

Total Value Per Share

$-1.86 - $-2.05

2. Growth of Adaptive Biotechnologies Corp (5 min.)




Is Adaptive Biotechnologies Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$308.2m$505.8m-$133.4m-35.8%

How much money is Adaptive Biotechnologies Corp making?

Current yearPrevious yearGrowGrow %
Making money-$57.3m-$45.9m-$11.3m-19.8%
Net Profit Margin-136.5%-104.8%--

How much money comes from the company's main activities?

3. Financial Health of Adaptive Biotechnologies Corp (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#177 / 1007

Most Revenue
#147 / 1007

Most Profit
#919 / 1007

Most Efficient
#585 / 1007

What can you expect buying and holding a share of Adaptive Biotechnologies Corp? (5 min.)

Welcome investor! Adaptive Biotechnologies Corp's management wants to use your money to grow the business. In return you get a share of Adaptive Biotechnologies Corp.

What can you expect buying and holding a share of Adaptive Biotechnologies Corp?

First you should know what it really means to hold a share of Adaptive Biotechnologies Corp. And how you can make/lose money.

Speculation

The Price per Share of Adaptive Biotechnologies Corp is $3.8. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adaptive Biotechnologies Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adaptive Biotechnologies Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.09. Based on the TTM, the Book Value Change Per Share is $-0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adaptive Biotechnologies Corp.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.47-12.4%-0.38-10.1%-0.34-8.9%-0.29-7.6%-0.26-6.9%
Usd Book Value Change Per Share-0.36-9.5%-0.26-7.0%-0.24-6.3%0.195.1%0.092.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.36-9.5%-0.26-7.0%-0.24-6.3%0.195.1%0.092.3%
Usd Price Per Share4.90-6.47-9.18-24.94-20.78-
Price to Earnings Ratio-2.60--4.35--6.67--28.88--24.06-
Price-to-Total Gains Ratio-13.53--26.17--39.06--109.48--109.48-
Price to Book Ratio2.34-2.53-2.64-4.22-3.52-
Price-to-Total Gains Ratio-13.53--26.17--39.06--109.48--109.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.8
Number of shares263
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.260.19
Usd Total Gains Per Share-0.260.19
Gains per Quarter (263 shares)-69.5250.54
Gains per Year (263 shares)-278.08202.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-278-2880202192
20-556-5660404394
30-834-8440606596
40-1112-11220809798
50-1390-1400010111000
60-1669-1678012131202
70-1947-1956014151404
80-2225-2234016171606
90-2503-2512018191808
100-2781-2790020222010

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.024.00.00.0%0.024.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%3.018.03.012.5%3.018.03.012.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.024.00.0%0.00.024.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%3.018.03.012.5%3.018.03.012.5%

Fundamentals of Adaptive Biotechnologies Corp

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Fundamental data was last updated by Penke on 2024-05-02 09:24:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Adaptive Biotechnologies Corp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Adaptive Biotechnologies Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • A Net Profit Margin of -151.7% means that $-1.52 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adaptive Biotechnologies Corp:

  • The MRQ is -151.7%. The company is making a huge loss. -2
  • The TTM is -136.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-151.7%TTM-136.5%-15.2%
TTM-136.5%YOY-104.8%-31.8%
TTM-136.5%5Y-122.7%-13.8%
5Y-122.7%10Y-117.3%-5.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-151.7%-184.9%+33.2%
TTM-136.5%-209.9%+73.4%
YOY-104.8%-267.4%+162.6%
5Y-122.7%-417.7%+295.0%
10Y-117.3%-593.8%+476.5%
1.1.2. Return on Assets

Shows how efficient Adaptive Biotechnologies Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • -10.5% Return on Assets means that Adaptive Biotechnologies Corp generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adaptive Biotechnologies Corp:

  • The MRQ is -10.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.5%TTM-7.9%-2.6%
TTM-7.9%YOY-5.4%-2.5%
TTM-7.9%5Y-4.9%-3.0%
5Y-4.9%10Y-4.3%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.5%-12.7%+2.2%
TTM-7.9%-12.2%+4.3%
YOY-5.4%-11.2%+5.8%
5Y-4.9%-13.4%+8.5%
10Y-4.3%-14.9%+10.6%
1.1.3. Return on Equity

Shows how efficient Adaptive Biotechnologies Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • -22.5% Return on Equity means Adaptive Biotechnologies Corp generated $-0.23 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adaptive Biotechnologies Corp:

  • The MRQ is -22.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.5%TTM-15.8%-6.8%
TTM-15.8%YOY-9.0%-6.8%
TTM-15.8%5Y-8.3%-7.5%
5Y-8.3%10Y-6.9%-1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.5%-16.3%-6.2%
TTM-15.8%-15.6%-0.2%
YOY-9.0%-13.9%+4.9%
5Y-8.3%-18.7%+10.4%
10Y-6.9%-19.6%+12.7%

1.2. Operating Efficiency of Adaptive Biotechnologies Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Adaptive Biotechnologies Corp is operating .

  • Measures how much profit Adaptive Biotechnologies Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • An Operating Margin of -99.7% means the company generated $-1.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adaptive Biotechnologies Corp:

  • The MRQ is -99.7%. The company is operating very inefficient. -2
  • The TTM is -122.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-99.7%TTM-122.9%+23.2%
TTM-122.9%YOY-112.4%-10.5%
TTM-122.9%5Y-125.6%+2.7%
5Y-125.6%10Y-120.7%-4.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-99.7%-336.0%+236.3%
TTM-122.9%-221.6%+98.7%
YOY-112.4%-281.8%+169.4%
5Y-125.6%-440.7%+315.1%
10Y-120.7%-567.1%+446.4%
1.2.2. Operating Ratio

Measures how efficient Adaptive Biotechnologies Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.00 means that the operating costs are $2.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 1.997. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.209. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.997TTM2.209-0.212
TTM2.209YOY2.124+0.085
TTM2.2095Y2.252-0.043
5Y2.25210Y2.204+0.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9973.110-1.113
TTM2.2093.238-1.029
YOY2.1243.647-1.523
5Y2.2525.416-3.164
10Y2.2047.364-5.160

1.3. Liquidity of Adaptive Biotechnologies Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Adaptive Biotechnologies Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.66 means the company has $4.66 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 4.660. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.973. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.660TTM4.973-0.312
TTM4.973YOY4.531+0.442
TTM4.9735Y5.838-0.866
5Y5.83810Y5.196+0.643
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6603.800+0.860
TTM4.9734.158+0.815
YOY4.5315.275-0.744
5Y5.8386.081-0.243
10Y5.1966.408-1.212
1.3.2. Quick Ratio

Measures if Adaptive Biotechnologies Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • A Quick Ratio of 7.57 means the company can pay off $7.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 7.575. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.982. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.575TTM7.982-0.407
TTM7.982YOY7.121+0.861
TTM7.9825Y9.368-1.386
5Y9.36810Y8.318+1.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.5753.419+4.156
TTM7.9823.909+4.073
YOY7.1215.230+1.891
5Y9.3686.030+3.338
10Y8.3186.388+1.930

1.4. Solvency of Adaptive Biotechnologies Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Adaptive Biotechnologies Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Adaptive Biotechnologies Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.53 means that Adaptive Biotechnologies Corp assets are financed with 53.4% credit (debt) and the remaining percentage (100% - 53.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 0.534. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.494. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.534TTM0.494+0.040
TTM0.494YOY0.405+0.089
TTM0.4945Y0.453+0.041
5Y0.45310Y0.451+0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5340.349+0.185
TTM0.4940.340+0.154
YOY0.4050.275+0.130
5Y0.4530.366+0.087
10Y0.4510.389+0.062
1.4.2. Debt to Equity Ratio

Measures if Adaptive Biotechnologies Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • A Debt to Equity ratio of 114.4% means that company has $1.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 1.144. The company is able to pay all its debts with equity. +1
  • The TTM is 0.981. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.144TTM0.981+0.163
TTM0.981YOY0.691+0.290
TTM0.9815Y0.656+0.325
5Y0.65610Y0.547+0.109
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1440.393+0.751
TTM0.9810.410+0.571
YOY0.6910.341+0.350
5Y0.6560.444+0.212
10Y0.5470.477+0.070

2. Market Valuation of Adaptive Biotechnologies Corp

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Adaptive Biotechnologies Corp generates.

  • Above 15 is considered overpriced but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • A PE ratio of -2.60 means the investor is paying $-2.60 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adaptive Biotechnologies Corp:

  • The EOD is -2.016. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.600. Based on the earnings, the company is expensive. -2
  • The TTM is -4.350. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.016MRQ-2.600+0.584
MRQ-2.600TTM-4.350+1.750
TTM-4.350YOY-6.671+2.321
TTM-4.3505Y-28.878+24.528
5Y-28.87810Y-24.065-4.813
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.016-2.302+0.286
MRQ-2.600-2.570-0.030
TTM-4.350-2.776-1.574
YOY-6.671-3.945-2.726
5Y-28.878-6.409-22.469
10Y-24.065-6.543-17.522
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adaptive Biotechnologies Corp:

  • The EOD is -4.959. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.395. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.191. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.959MRQ-6.395+1.436
MRQ-6.395TTM-6.191-0.203
TTM-6.191YOY-6.848+0.657
TTM-6.1915Y-23.557+17.365
5Y-23.55710Y-19.631-3.926
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.959-3.025-1.934
MRQ-6.395-3.437-2.958
TTM-6.191-3.598-2.593
YOY-6.848-5.240-1.608
5Y-23.557-8.339-15.218
10Y-19.631-8.910-10.721
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Adaptive Biotechnologies Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.34 means the investor is paying $2.34 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Adaptive Biotechnologies Corp:

  • The EOD is 1.817. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.342. Based on the equity, the company is underpriced. +1
  • The TTM is 2.532. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.817MRQ2.342-0.526
MRQ2.342TTM2.532-0.190
TTM2.532YOY2.644-0.111
TTM2.5325Y4.220-1.688
5Y4.22010Y3.517+0.703
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8171.998-0.181
MRQ2.3422.069+0.273
TTM2.5322.095+0.437
YOY2.6442.786-0.142
5Y4.2203.617+0.603
10Y3.5174.038-0.521
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Adaptive Biotechnologies Corp.

3.1. Institutions holding Adaptive Biotechnologies Corp

Institutions are holding 94.068% of the shares of Adaptive Biotechnologies Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Viking Global Investors LP20.67220.53832999370800
2023-12-31ARK Investment Management LLC8.82650.371512806513129720511.2709
2023-12-31Vanguard Group Inc8.79970.0014127676845186424.2341
2023-12-31Matrix Capital Management Company, LLC7.9760.58361157259000
2023-12-31BlackRock Inc7.87190.001411421554-163554-1.4118
2023-12-31Nikko Asset Management Americas Inc4.48790.30676511659-59280-0.9022
2023-12-31Sumitomo Mitsui Trust Holdings Inc4.48790.02366511659-59280-0.9022
2023-09-30Point72 Asset Management, L.P.3.93770.0909571330057133000
2023-12-31Pictet Asset Manangement SA2.35870.0185342235637965212.4775
2023-12-31Aristotle Atlantic Partners, LLC2.10260.52613050684-7522-0.246
2023-12-31Rubric Capital Management LP1.9730.2911286272928627290
2023-12-31Massachusetts Financial Services Company1.79440.0041260350063204032.0595
2023-12-31State Street Corporation1.78620.00062591653566122.2332
2023-12-31Geode Capital Management, LLC1.73930.001325236421077634.4606
2023-12-31Dimensional Fund Advisors, Inc.1.47370.00312138191-152986-6.6772
2023-12-31Blue Water Life Science Advisors, LLC1.16327.24351687665-690000-29.0201
2023-12-31Goldman Sachs Group Inc1.10830.00071608120-89054-5.2472
2023-12-31Gilder Gagnon Howe & CO LLC0.85020.083123351493960.7676
2023-12-31Eagle Health Investments LP0.83731.2096121486000
2023-12-31Federated Hermes Inc0.83580.01481212660-172547-12.4564
Total 85.082511.3138123448241+10183116+8.2%

3.2. Funds holding Adaptive Biotechnologies Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31ARK Genomic Revolution7.21562.091110469349-2226928-17.54
2024-03-31ARK Genomic Revolution ETF7.19632.09211044127800
2024-02-29Nikko AM ARK Pstv Chg Innovt P JPY Acc2.92680.69264246564-54892-1.2761
2024-03-31Vanguard Total Stock Mkt Idx Inv2.81960.0008409095563060.1544
2024-03-31Vanguard Small Cap Index2.29010.00733322688-36287-1.0803
2024-03-28iShares Russell 2000 ETF1.94620.0138282375313620.0483
2024-03-31Vanguard Small Cap Growth Index Inv1.29960.016718856576690.0355
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr1.16740.00521693804304511.8307
2024-03-31Aristotle Atlantic Focus Growth Equity1.13670.5438164930000
2023-10-13Pictet Biopharmaceutical Mother1.06940.4601155160060437363.8045
2024-03-31MFS New Discovery I0.98660.1834143154400
2024-01-31Fidelity Small Cap Index0.79120.0171148006148421.3098
2024-03-28iShares Biotechnology ETF0.73990.0452107360000
2024-03-31BlackRock Advantage Small Cap Core Instl0.56290.072381675700
2023-12-19Nomura ACI AdvMed Impact Inv MF0.54480.35877904467904611.1113
2024-03-28iShares Russell 2000 Growth ETF0.50210.0201728443-847-0.1161
2024-03-31State St Russell Sm/Mid Cp® Indx NL Cl C0.46710.00567769200
2024-03-31abrdn Healthcare Investors0.44650.206264778700
2023-12-31Federated Hermes MDT Mid Cap Growth A0.44610.3955647222-39153-5.7043
2023-12-31Federated Hermes MDT MCG Institutional0.44610.3961647222-39153-5.7043
Total 35.0017.62350783667-1660211-3.3%

3.3. Insider Transactions

Insiders are holding 2.786% of the shares of Adaptive Biotechnologies Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-05Chad M RobinsSELL486733.43
2024-03-05Julie RubinsteinSELL390703.47
2024-03-05Kyle PiskelSELL77273.43
2024-03-05Stacy L TaylorSELL133813.43
2024-03-05Tycho PetersonSELL154563.44
2023-11-16Kyle PiskelSELL2594.13
2023-08-07Nitin SoodSELL56526.78
2023-06-20Tycho PetersonSELL1349618.14
2023-06-15Tycho PetersonSELL700008.53
2023-06-02Tycho PetersonSELL380007.16

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Adaptive Biotechnologies Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.362-0.264-27%-0.238-34%0.192-288%0.087-515%
Book Value Per Share--2.0922.527-17%3.433-39%3.375-38%2.740-24%
Current Ratio--4.6604.973-6%4.531+3%5.838-20%5.196-10%
Debt To Asset Ratio--0.5340.494+8%0.405+32%0.453+18%0.451+18%
Debt To Equity Ratio--1.1440.981+17%0.691+65%0.656+74%0.547+109%
Dividend Per Share----0%-0%-0%-0%
Eps---0.471-0.382-19%-0.340-28%-0.288-39%-0.262-44%
Free Cash Flow Per Share---0.192-0.283+48%-0.340+77%-0.202+6%-0.179-6%
Free Cash Flow To Equity Per Share---0.191-0.280+46%-0.115-40%0.061-414%0.040-576%
Gross Profit Margin--1.3151.396-6%1.583-17%1.486-11%1.495-12%
Intrinsic Value_10Y_max---4.141--------
Intrinsic Value_10Y_min---3.950--------
Intrinsic Value_1Y_max---1.265--------
Intrinsic Value_1Y_min---1.243--------
Intrinsic Value_3Y_max---3.152--------
Intrinsic Value_3Y_min---3.022--------
Intrinsic Value_5Y_max---4.259--------
Intrinsic Value_5Y_min---4.009--------
Market Cap559998400.000-29%722103200.000953839380.000-24%1353206660.000-47%3675578972.000-80%3062982476.667-76%
Net Profit Margin---1.517-1.365-10%-1.048-31%-1.227-19%-1.173-23%
Operating Margin---0.997-1.229+23%-1.124+13%-1.256+26%-1.207+21%
Operating Ratio--1.9972.209-10%2.124-6%2.252-11%2.204-9%
Pb Ratio1.817-29%2.3422.532-8%2.644-11%4.220-44%3.517-33%
Pe Ratio-2.016+22%-2.600-4.350+67%-6.671+157%-28.878+1011%-24.065+826%
Price Per Share3.800-29%4.9006.473-24%9.183-47%24.942-80%20.785-76%
Price To Free Cash Flow Ratio-4.959+22%-6.395-6.191-3%-6.848+7%-23.557+268%-19.631+207%
Price To Total Gains Ratio-10.495+22%-13.533-26.169+93%-39.056+189%-109.481+709%-109.481+709%
Quick Ratio--7.5757.982-5%7.121+6%9.368-19%8.318-9%
Return On Assets---0.105-0.079-25%-0.054-48%-0.049-53%-0.043-59%
Return On Equity---0.225-0.158-30%-0.090-60%-0.083-63%-0.069-69%
Total Gains Per Share---0.362-0.264-27%-0.238-34%0.192-288%0.087-515%
Usd Book Value--308278000.000372458500.000-17%505870750.000-39%497424600.000-38%403765833.333-24%
Usd Book Value Change Per Share---0.362-0.264-27%-0.238-34%0.192-288%0.087-515%
Usd Book Value Per Share--2.0922.527-17%3.433-39%3.375-38%2.740-24%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.471-0.382-19%-0.340-28%-0.288-39%-0.262-44%
Usd Free Cash Flow---28230000.000-41755250.000+48%-50073500.000+77%-29803500.000+6%-26443625.000-6%
Usd Free Cash Flow Per Share---0.192-0.283+48%-0.340+77%-0.202+6%-0.179-6%
Usd Free Cash Flow To Equity Per Share---0.191-0.280+46%-0.115-40%0.061-414%0.040-576%
Usd Market Cap559998400.000-29%722103200.000953839380.000-24%1353206660.000-47%3675578972.000-80%3062982476.667-76%
Usd Price Per Share3.800-29%4.9006.473-24%9.183-47%24.942-80%20.785-76%
Usd Profit---69441000.000-57322000.000-17%-45961000.000-34%-41766950.000-40%-36741083.333-47%
Usd Revenue--45784000.00042569000.000+8%46327000.000-1%34669050.000+32%31210166.667+47%
Usd Total Gains Per Share---0.362-0.264-27%-0.238-34%0.192-288%0.087-515%
 EOD+3 -5MRQTTM+12 -22YOY+10 -245Y+9 -2510Y+6 -28

4.2. Fundamental Score

Let's check the fundamental score of Adaptive Biotechnologies Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.016
Price to Book Ratio (EOD)Between0-11.817
Net Profit Margin (MRQ)Greater than0-1.517
Operating Margin (MRQ)Greater than0-0.997
Quick Ratio (MRQ)Greater than17.575
Current Ratio (MRQ)Greater than14.660
Debt to Asset Ratio (MRQ)Less than10.534
Debt to Equity Ratio (MRQ)Less than11.144
Return on Equity (MRQ)Greater than0.15-0.225
Return on Assets (MRQ)Greater than0.05-0.105
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Adaptive Biotechnologies Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.762
Ma 20Greater thanMa 502.849
Ma 50Greater thanMa 1003.068
Ma 100Greater thanMa 2003.660
OpenGreater thanClose3.510
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -4,1162,211-1,9051,012-893643-250465215
Long-term Assets Other  4,462344,4961,7796,275-3715,904-7,441-1,537



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets661,134
Total Liabilities352,856
Total Stockholder Equity308,399
 As reported
Total Liabilities 352,856
Total Stockholder Equity+ 308,399
Total Assets = 661,134

Assets

Total Assets661,134
Total Current Assets410,188
Long-term Assets250,946
Total Current Assets
Cash And Cash Equivalents 65,064
Short-term Investments 281,337
Net Receivables 38,969
Inventory 14,448
Other Current Assets 10,370
Total Current Assets  (as reported)410,188
Total Current Assets  (calculated)410,188
+/- 0
Long-term Assets
Property Plant Equipment 120,323
Goodwill 118,972
Intangible Assets 5,128
Long-term Assets  (as reported)250,946
Long-term Assets  (calculated)244,423
+/- 6,523

Liabilities & Shareholders' Equity

Total Current Liabilities88,015
Long-term Liabilities264,841
Total Stockholder Equity308,399
Total Current Liabilities
Short-term Debt 9,384
Accounts payable 7,719
Other Current Liabilities 22,282
Total Current Liabilities  (as reported)88,015
Total Current Liabilities  (calculated)39,385
+/- 48,630
Long-term Liabilities
Capital Lease Obligations 98,772
Long-term Liabilities Other 130,660
Long-term Liabilities  (as reported)264,841
Long-term Liabilities  (calculated)229,432
+/- 35,409
Total Stockholder Equity
Common Stock14
Retained Earnings -1,144,332
Accumulated Other Comprehensive Income 215
Other Stockholders Equity 1,452,502
Total Stockholder Equity (as reported)308,399
Total Stockholder Equity (calculated)308,399
+/-0
Other
Capital Stock14
Cash and Short Term Investments 346,401
Common Stock Shares Outstanding 144,901
Current Deferred Revenue48,630
Liabilities and Stockholders Equity 661,134
Net Debt 164,368
Net Invested Capital 308,399
Net Working Capital 322,173
Property Plant and Equipment Gross 193,557
Short Long Term Debt Total 229,432



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
332,688
614,584
601,395
917,392
912,302
874,886
854,822
1,095,473
1,116,414
1,072,093
1,033,374
992,607
923,344
858,193
806,633
884,208
856,617
791,463
764,540
717,682
661,134
661,134717,682764,540791,463856,617884,208806,633858,193923,344992,6071,033,3741,072,0931,116,4141,095,473854,822874,886912,302917,392601,395614,584332,688000
   > Total Current Assets 
0
0
0
180,718
459,148
442,301
601,356
612,690
584,646
599,521
877,358
726,914
764,960
643,729
467,027
402,748
419,120
438,575
564,380
562,146
501,333
476,809
435,237
410,188
410,188435,237476,809501,333562,146564,380438,575419,120402,748467,027643,729764,960726,914877,358599,521584,646612,690601,356442,301459,148180,718000
       Cash And Cash Equivalents 
0
0
0
55,030
111,290
48,458
74,941
96,576
212,688
365,440
497,076
123,436
173,624
184,186
122,401
139,065
114,805
76,412
217,552
90,030
94,612
109,240
88,713
65,064
65,06488,713109,24094,61290,030217,55276,412114,805139,065122,401184,186173,624123,436497,076365,440212,68896,57674,94148,458111,29055,030000
       Short-term Investments 
0
0
0
109,988
329,150
374,543
498,487
480,290
342,485
204,940
338,004
564,833
540,640
414,227
292,639
213,996
248,757
307,326
290,527
408,166
346,083
307,990
282,419
281,337
281,337282,419307,990346,083408,166290,527307,326248,757213,996292,639414,227540,640564,833338,004204,940342,485480,290498,487374,543329,150109,988000
       Net Receivables 
0
0
0
4,807
4,066
7,252
9,257
12,676
9,382
7,914
11,858
10,047
19,754
14,174
17,122
17,409
22,518
23,712
26,549
40,057
30,972
31,545
31,211
38,969
38,96931,21131,54530,97240,05726,54923,71222,51817,40917,12214,17419,75410,04711,8587,9149,38212,6769,2577,2524,0664,807000
       Other Current Assets 
0
0
0
3,055
6,787
4,044
10,004
14,079
9,573
10,691
19,684
14,535
13,520
12,530
16,634
13,015
12,038
12,347
12,407
9,440
9,792
9,074
13,404
10,370
10,37013,4049,0749,7929,44012,40712,34712,03813,01516,63412,53013,52014,53519,68410,6919,57314,07910,0044,0446,7873,055000
   > Long-term Assets 
0
0
0
151,970
155,436
159,094
316,036
299,612
290,240
255,301
218,115
389,500
307,133
389,645
525,580
520,596
439,073
368,058
319,828
294,471
290,130
287,731
282,445
250,946
250,946282,445287,731290,130294,471319,828368,058439,073520,596525,580389,645307,133389,500218,115255,301290,240299,612316,036159,094155,436151,970000
       Property Plant Equipment 
0
0
0
19,125
21,184
22,298
46,542
60,355
56,010
64,452
68,889
139,042
144,812
167,302
177,266
172,940
171,628
171,250
169,267
164,210
160,254
156,499
152,012
120,323
120,323152,012156,499160,254164,210169,267171,250171,628172,940177,266167,302144,812139,04268,88964,45256,01060,35546,54222,29821,18419,125000
       Goodwill 
0
0
0
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972000
       Long Term Investments 
0
0
0
0
0
0
135,306
105,435
100,618
57,383
16,466
118,525
30,688
91,131
217,379
217,145
137,110
66,928
19,698
0
0
0
0
0
0000019,69866,928137,110217,145217,37991,13130,688118,52516,46657,383100,618105,435135,306000000
       Intangible Assets 
0
0
0
13,626
13,207
12,784
12,356
11,928
11,504
11,081
10,653
10,225
9,806
9,383
8,955
8,526
8,107
7,684
7,256
6,827
6,408
5,985
5,557
5,128
5,1285,5575,9856,4086,8277,2567,6848,1078,5268,9559,3839,80610,22510,65311,08111,50411,92812,35612,78413,20713,626000
       Other Assets 
0
0
0
0
2,073
5,040
2,860
39,529
3,136
3,413
3,135
2,736
2,855
2,857
3,008
3,013
3,256
3,224
4,635
4,462
4,496
0
0
0
0004,4964,4624,6353,2243,2563,0133,0082,8572,8552,7363,1353,4133,13639,5292,8605,0402,0730000
> Total Liabilities 
0
0
0
590,800
326,486
885,769
331,467
341,263
323,323
324,883
320,426
373,148
346,376
340,064
341,064
319,242
304,938
288,317
396,394
392,519
367,511
368,573
356,045
352,856
352,856356,045368,573367,511392,519396,394288,317304,938319,242341,064340,064346,376373,148320,426324,883323,323341,263331,467885,769326,486590,800000
   > Total Current Liabilities 
0
0
0
22,800
63,251
74,862
73,377
78,313
77,950
93,422
100,832
105,197
106,768
116,648
122,382
113,807
115,066
111,468
104,018
109,788
90,101
95,335
93,298
88,015
88,01593,29895,33590,101109,788104,018111,468115,066113,807122,382116,648106,768105,197100,83293,42277,95078,31373,37774,86263,25122,800000
       Short-term Debt 
0
0
0
0
0
0
0
0
1,502
3,229
3,969
3,529
4,308
4,833
5,108
5,055
8,545
8,615
8,528
9,230
9,287
9,345
9,482
9,384
9,3849,4829,3459,2879,2308,5288,6158,5455,0555,1084,8334,3083,5293,9693,2291,50200000000
       Accounts payable 
0
0
0
1,793
3,266
2,944
2,421
4,453
3,895
3,686
5,412
3,237
5,197
6,093
8,252
3,307
5,959
2,720
4,163
8,084
6,333
9,163
4,483
7,719
7,7194,4839,1636,3338,0844,1632,7205,9593,3078,2526,0935,1973,2375,4123,6863,8954,4532,4212,9443,2661,793000
       Other Current Liabilities 
0
0
0
8,312
7,961
10,724
9,687
12,866
7,981
10,808
13,259
25,112
18,915
22,169
29,068
24,985
17,058
19,219
23,435
28,359
14,161
18,910
23,993
22,282
22,28223,99318,91014,16128,35923,43519,21917,05824,98529,06822,16918,91525,11213,25910,8087,98112,8669,68710,7247,9618,312000
   > Long-term Liabilities 
0
0
0
568,000
263,235
810,907
258,090
262,950
245,373
231,461
219,594
267,951
239,608
223,416
218,682
205,435
189,872
176,849
292,376
282,731
277,410
273,238
262,747
264,841
264,841262,747273,238277,410282,731292,376176,849189,872205,435218,682223,416239,608267,951219,594231,461245,373262,950258,090810,907263,235568,000000
       Long term Debt Total 
0
0
0
0
353
2,602
23,449
36,607
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000036,60723,4492,6023530000
       Other Liabilities 
0
0
0
0
263,235
246,374
234,641
226,343
208,828
188,958
177,228
163,618
144,356
119,642
110,638
98,750
84,894
74,122
191,855
183,959
180,916
0
0
0
000180,916183,959191,85574,12284,89498,750110,638119,642144,356163,618177,228188,958208,828226,343234,641246,374263,2350000
       Deferred Long Term Liability 
0
0
0
0
0
4,800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000004,80000000
> Total Stockholder Equity
-224,616
0
0
-258,112
288,098
-284,374
585,925
571,039
551,563
529,939
775,047
743,266
725,588
693,181
651,509
603,992
553,205
518,304
487,840
464,165
424,020
396,036
361,732
308,399
308,399361,732396,036424,020464,165487,840518,304553,205603,992651,509693,181725,588743,266775,047529,939551,563571,039585,925-284,374288,098-258,11200-224,616
   Common Stock
0
0
0
1
11
1
12
12
12
12
13
14
14
14
14
14
14
14
14
14
14
14
14
14
1414141414141414141414141413121212121111000
   Retained Earnings Total Equity000-976,781-919,082-878,954-833,673-781,627-718,891-657,458-601,555-552,254-511,61200000000000
   Accumulated Other Comprehensive Income 
0
0
0
-107
92
382
572
671
3,313
2,153
1,427
893
631
216
7
-1,137
-4,783
-5,800
-5,971
-4,116
-1,905
-893
-250
215
215-250-893-1,905-4,116-5,971-5,800-4,783-1,13772166318931,4272,1533,31367157238292-107000
   Capital Surplus 
0
0
0
0
40,981
46,160
930,208
935,834
945,026
0
0
1,253,971
1,277,197
1,294,506
1,308,946
1,324,006
1,339,601
1,357,763
1,372,751
1,387,349
1,402,692
0
0
0
0001,402,6921,387,3491,372,7511,357,7631,339,6011,324,0061,308,9461,294,5061,277,1971,253,97100945,026935,834930,20846,16040,9810000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
37,902
602,543
43,558
12,816
935,834
945,026
958,097
1,240,649
1,253,971
1,277,197
1,294,506
1,308,946
1,324,006
1,339,601
1,357,763
1,372,751
1,387,349
1,402,692
1,421,506
1,436,859
1,452,502
1,452,5021,436,8591,421,5061,402,6921,387,3491,372,7511,357,7631,339,6011,324,0061,308,9461,294,5061,277,1971,253,9711,240,649958,097945,026935,83412,81643,558602,54337,902000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue170,276
Cost of Revenue-97,784
Gross Profit72,49272,492
 
Operating Income (+$)
Gross Profit72,492
Operating Expense-274,098
Operating Income-201,606-201,606
 
Operating Expense (+$)
Research Development101,585
Selling General Administrative83,934
Selling And Marketing Expenses88,579
Operating Expense274,098274,098
 
Net Interest Income (+$)
Interest Income13,520
Interest Expense-13,800
Other Finance Cost-573
Net Interest Income-853
 
Pretax Income (+$)
Operating Income-201,606
Net Interest Income-853
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-225,304-177,908
EBIT - interestExpense = -215,406
-225,304
-211,450
Interest Expense13,800
Earnings Before Interest and Taxes (EBIT)-201,606-211,504
Earnings Before Interest and Taxes (EBITDA)-179,375
 
After tax Income (+$)
Income Before Tax-225,304
Tax Provision-0
Net Income From Continuing Ops-196,006-225,304
Net Income-225,250
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses371,882
Total Other Income/Expenses Net-23,698853
 

Technical Analysis of Adaptive Biotechnologies Corp
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Adaptive Biotechnologies Corp. The general trend of Adaptive Biotechnologies Corp is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Adaptive Biotechnologies Corp's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Adaptive Biotechnologies Corp.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 4.345 < 4.38 < 4.49.

The bearish price targets are: 3.52 > 3.12 > 2.28.

Tweet this
Adaptive Biotechnologies Corp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Adaptive Biotechnologies Corp. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Adaptive Biotechnologies Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Adaptive Biotechnologies Corp. The current macd is 0.14311482.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Adaptive Biotechnologies Corp price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Adaptive Biotechnologies Corp. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Adaptive Biotechnologies Corp price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Adaptive Biotechnologies Corp Daily Moving Average Convergence/Divergence (MACD) ChartAdaptive Biotechnologies Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Adaptive Biotechnologies Corp. The current adx is 22.80.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Adaptive Biotechnologies Corp shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Adaptive Biotechnologies Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Adaptive Biotechnologies Corp. The current sar is 2.81402607.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Adaptive Biotechnologies Corp Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Adaptive Biotechnologies Corp. The current rsi is 70.76. The current phase is Overbought in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bear market: Short-term excessive buying, potential for relief decline. Consider shorting, be cautious of potential pullback. -1
  • Trending up: The RSI is trending up. +1
Adaptive Biotechnologies Corp Daily Relative Strength Index (RSI) ChartAdaptive Biotechnologies Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Adaptive Biotechnologies Corp. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Adaptive Biotechnologies Corp price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Adaptive Biotechnologies Corp Daily Stochastic Oscillator ChartAdaptive Biotechnologies Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Adaptive Biotechnologies Corp. The current cci is 183.44.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Adaptive Biotechnologies Corp Daily Commodity Channel Index (CCI) ChartAdaptive Biotechnologies Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Adaptive Biotechnologies Corp. The current cmo is 60.53.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Adaptive Biotechnologies Corp Daily Chande Momentum Oscillator (CMO) ChartAdaptive Biotechnologies Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Adaptive Biotechnologies Corp. The current willr is -8.78378378.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Adaptive Biotechnologies Corp Daily Williams %R ChartAdaptive Biotechnologies Corp Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Adaptive Biotechnologies Corp. The current atr is 0.2882781.

Adaptive Biotechnologies Corp Daily Average True Range (ATR) ChartAdaptive Biotechnologies Corp Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Adaptive Biotechnologies Corp. The current obv is 18,721,029.

Adaptive Biotechnologies Corp Daily On-Balance Volume (OBV) ChartAdaptive Biotechnologies Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Adaptive Biotechnologies Corp. The current mfi is 86.23.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Adaptive Biotechnologies Corp Daily Money Flow Index (MFI) ChartAdaptive Biotechnologies Corp Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Adaptive Biotechnologies Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Adaptive Biotechnologies Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Adaptive Biotechnologies Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.762
Ma 20Greater thanMa 502.849
Ma 50Greater thanMa 1003.068
Ma 100Greater thanMa 2003.660
OpenGreater thanClose3.510
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Adaptive Biotechnologies Corp with someone you think should read this too:
  • Are you bullish or bearish on Adaptive Biotechnologies Corp? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Adaptive Biotechnologies Corp? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Adaptive Biotechnologies Corp

I send you an email if I find something interesting about Adaptive Biotechnologies Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Adaptive Biotechnologies Corp.

Receive notifications about Adaptive Biotechnologies Corp in your mailbox!